Significant differences were found in many more domains of the two questionnaires between mMRC grades than between GOLD stages. In the multiple linear regression model, the mMRC scale was the only factor that remained determinative of all the domains of SGRQ and WHOQOL-BREF. Patients with chronic productive cough, sleep disorders and frequent exacerbations had poorer HRQoL, as reflected by higher scores in SGRQ or lower scores in WHOQOL-BREF.
I NTRO D U C TIO N
Chronic obstructive pulmonary disease (COPD), a chronic respiratory disease with high prevalence worldwide, is becoming a leading cause of mortality and morbidity. (1) Healthrelated quality of life (HRQoL) is a patient-reported outcome that is receiving increasing recognition regarding its use in patients with COPD. (2, 3) HRQoL offers an integral measurement of overall health status and the impact of disease on patients.
In COPD clinical trials, HRQoL is frequently included as an endpoint to evaluate the effects of pharmacological and non-pharmacological treatments. (4) (5) (6) (7) In addition, HRQoL also predicts mortality and hospitalisation in patients with COPD. (2, 8, 9) HRQoL is generally measured using validated questionnaires, either disease-specific or generic, and a comprehensive evaluation of HRQoL should enclose both disease-specific and generic instruments. (10) However, since the application of HRQoL questionnaires in daily clinical practice is often restricted due to time constraints, a simple surrogate marker that is discriminative of HRQoL would be helpful.
A spirometric classification of COPD (Stages 1 to 4), based on forced expiratory volume in 1 second (FEV1) percentage predicted, had been advocated by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). However, the cutoff points recommended are used for the purpose of simplicity and have not been clinically validated. (1) Furthermore, FEV1 is often poorly correlated with patient-centred outcomes such as HRQoL. (11) (12) (13) The modified Medical Research Council (mMRC) scale is a five-level rating scale based on the patient's perception of dyspnoea in daily activities. (14) For patients with COPD, it is a simple and valid tool to assess disability, (15) and has been reported to be more relevant to patients' health and psychological status than FEV1. (16) To the best of our knowledge, since the GOLD spirometric classification was published, no study has reported direct comparisons between these two indices to categorise patients with COPD with regard to HRQoL.
In this cross-sectional observational study, we compared the discriminative capacity of the GOLD spirometric classification
The modified Medical Research Council dyspnoea scale is a good indicator of health-related quality of life in patients with chronic obstructive pulmonary disease INTRODUCTION Health-related quality of life (HRQoL) is an important patient-centred outcome in chronic obstructive pulmonary disease (COPD). The aim of the current study is to compare the discriminative capacity of the modified Medical Research Council (mMRC) dyspnoea scale and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric classification of COPD on HRQoL, as well as determine other factors that are simple and determinative of HRQoL.
METHODS
In this cross-sectional observational study, a total of 328 patients with COPD were enrolled from the pulmonology outpatient clinic. HRQoL was measured using the St George's Respiratory Questionnaire (SGRQ) and the World Health Organization Quality of Life-BREF (WHOQOL-BREF). HRQoL scores were compared between the four GOLD stages and the five grades of the mMRC scale. Significant differences were determined using analysis of variance with Scheffe post-hoc test. Multiple linear regression was applied to explore the major determinants of HRQoL and exclude confounding factors.
and the mMRC dyspnoea scale with regard to HRQoL.
The St George's Respiratory Questionnaire (SGRQ), a diseasespecific questionnaire, and the World Health Organization Quality of Life-BREF (WHOQOL-BREF), a generic questionnaire, were used to measure HRQoL.
M E TH O DS
A total of 328 patients were consecutively recruited from the pulmonology outpatient clinic of a teaching hospital in southern Taiwan between September 2007 and December 2009. The criteria for participation included an age of 40 years or more, and a diagnosis of COPD based on medical history and a post-bronchodilator FEV1 to forced vital capacity (FVC) ratio (FEV1/FVC) of < 0.7. Patients with a history of asthma, active pulmonary tuberculosis, lung cancer or pulmonary resection were excluded. All of the recruited patients were clinically stable for at least four weeks prior to recruitment, without the need for a change in treatment regimens. The protocol was approved by the local ethics committee and all participating patients signed an informed consent form.
Patient demographic data such as age, gender, body mass index (BMI), level of education and smoking status were recorded. Any history of hypertension, diabetes, cardiovascular disease and sleep disorders, which are the most commonly reported comorbid conditions in both COPD patients (17) (18) (19) and the general population, was also collected based on the International Classification of Diseases, Ninth Revision, codes in the local hospital information system. Hypertension, diabetes mellitus and sleep disorders include codes 250, 401-405 and 7805, respectively. Cardiovascular disease, denoted by a history of myocardial infarction, angina pectoris, ischaemic heart disease and heart failure, was coded as 410-414 and 428. Each patient was also asked to report on any symptoms experienced that were associated with chronic bronchitis (e.g. cough with sputum expectoration for at least three months per year over a period of two consecutive years). The number of exacerbations that occurred in the patients within the previous year was also acquired. The patients were categorised by GOLD spirometric classification (with cutoff points of 80%, 50% and 30% FEV1 percentage predicted) and mMRC grades for statistical analysis.
Spirometry measurements were carried out according to the American Thoracic Society/European Respiratory Society guidelines, (20) on the same day the quality of life questionnaires were collected, and using the HI701 spirometer (CHEST MI Inc, Tokyo, Japan). Post-bronchodilator tests were performed 15 minutes after the administration of 400 μg of salbutamol via a metred-dose inhaler with a spacer. Reference FEV1 and FVC values were calculated as previously described.
The degree of dyspnoea was rated as previously described in the Mahler and Wells study (14) 
RESULTS
The baseline characteristics of the 328 enrolled patients are summarised in Table I . The mean patient age was 72.1 years (range 43-99 years) and most patients were male (89%).
Only 21% of the participants had a junior high school education or above. About a third (38.4%) of the patients were smokers at the time the study was conducted, and about half (44.5%) of the patients suffered from chronic productive cough. The patients experienced an average of about one exacerbation within the previous year. Significantly different scores between GOLD stages were found in all domains of SGRQ, but only in the Physical domain of WHOQOL-BREF. Post-hoc analysis showed that significant differences between GOLD stages were found mostly in SGRQ.
There was significant overlap of the scores across GOLD stages, and the major changes between consecutive stages were found to occur between GOLD stages 2 and 3.
The mean domain scores stratified according to mMRC grades are presented in Table III . An increase in mMRC grade was accompanied by a deterioration in HRQoL, evidenced by increased SGRQ and reduced WHOQOL-BREF domain scores. All domain scores differed significantly among mMRC grades, implying that the mMRC scale had a better discriminative capacity than GOLD staging in HRQoL. Posthoc analysis showed significant differences in more domains of the two questionnaires among mMRC grades than among GOLD stages. There was much less overlap of the scores across mMRC grades, and most of the changes occurred evenly throughout all the grades. Table IV summarises 
DISCUSSION
To the best of our knowledge, the present study is the first study to investigate the determinant factors of HRQoL in patients with COPD of all levels of severity, using both disease-specific and generic questionnaires. We found inconsistencies between the GOLD spirometric classification of COPD and HRQoL, as measured by both SGRQ and WHOQOL-BREF. We also found that the mMRC scale had better discriminative capacity than the GOLD classification in the evaluation of HRQoL, as evidenced by the results of both the ANOVA and multiple linear regression models.
Although COPD is characterised by airflow limitations, it involves several systemic components. (1, 26, 27) HRQoL, a comprehensive and widely accepted measure of the impact of disease on a patient's quality of life, may help medical staff optimise treatment and help patients plan for the increasing disability associated with the disease. (28) Questionnaires such as SGRQ and WHOQOL-BREF are good tools for gauging
HRQoL, but their use in clinical practice is limited due to time constraints. Spirometry provides a useful measure of the pathological changes in COPD, but poorly correlates with some important outcomes. (27) As shown in the present study, as well as in previously published data, there is considerable heterogeneity in HRQoL impairment within each GOLD stage of severity. (3) It has also been demonstrated that the level of dyspnoea may be a more accurate measure of the HRQoL of patients with COPD compared to measurement by categorisation of spirometry results.
The MRC dyspnoea scale has been utilised for many years to grade disability resulting from breathlessness. (14, 29) It is short, simple to execute and can be easily performed in clinical settings. Its five consecutive questions describe patients' daily activities, and this explains why it correlates best with the SGRQ Activity and WHOQOL-BREF Physical domains, as was observed in the present study. The mMRC scale also demonstrated excellent discriminative capabilities in other domains such as the Impact, Psychological and Social domains, thus proving to be a good indicator of HRQoL.
When categorised using GOLD stages, the participants' HRQoL showed considerable variation and was not well distinguished. Nevertheless, the domain scores of SGRQ were significantly increased between stages 2 and 3; this was not observed between other consecutive stages. Our findings are consistent with reports by Jones et al (3) , Antonelli-Incalzi et al (11) and Hajiro et al (12) , which found that there was dramatic The present study's multiple linear regression analysis showed that other parameters were also determining factors of HRQoL. 'Chronic productive cough', a symptom that is routinely reported in both in-and outpatient settings, had a negative effect on the HRQoL of patients with COPD. This is noteworthy because although the symptoms 'cough' and 'sputum production' were mentioned in only five of the 50 items of SGRQ, these symptoms showed extensive influence on most of the SGRQ domains. Exacerbations of COPD also showed an adverse influence on HRQoL, compatible with the findings of previous studies. (32, 33) Sleep disorders, especially sleep apnoea, are associated with increased mortality and hospitalisation of COPD patients, (19) and in our study, sleep disorders also showed a detrimental impact on HRQoL. Aging 
There are some limitations in the present study. First, the number of participants in GOLD stages 1 and 4 were significantly lesser than those in GOLD stages 2 and 3. This unbalanced representation of patients has also been observed in the literature. (3, 11, 35) In general, most patients do not seek medical treatment until they are symptomatic, and thus present with relatively bad lung function at the time of diagnosis. On the other hand, patients diagnosed with severely impaired lung function (i.e. GOLD stage 4) are frequently hospitalised due to acute exacerbation, and are thus prone to become dependent on mechanical ventilation. These patients are also more inclined to have cardiovascular events and lung cancer, which increases mortality. We postulate that these are the reasons why we had fewer patients in GOLD stages 1 and 4.
Furthermore, our participants were recruited from an outpatient clinic. A thorough and well-designed survey on community populations may be able to overcome this limitation. The second limitation of our study was that most of our participants were male. This may be due to the fact that in Taiwan, a large proportion (55%-60%) of men are smokers while only a small proportion (3%-4%) of women smoke, (36) and cigarette smoking is a well-known risk factor for COPD. Although multiple linear regression analysis did not show significant difference in HRQoL between men and women with COPD, we believe that further studies with a more balanced sample of men and women are needed.
In conclusion, the mMRC dyspnoea scale is a concise and practical tool to assess the HRQoL of patients with COPD in daily clinical practice. Compared to GOLD staging, it demonstrates better discriminative validity in evaluating HRQoL and is able to detect impaired health status earlier. In addition to decreased lung function, chronic productive cough, sleep disorders and frequent exacerbations also have negative effects on HRQoL. Therefore, these factors should be taken into consideration when HRQoL is included as a measurement of patients' baseline condition or treatment effects.
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